CBDL President Visits Healthcare+ Expo Taiwan, Explores Taiwan Partnerships to Advance Brazil’s Diagnostics Sector

📣Unlock New MedTech Partnerships in Asia!
【2025 Registration Opens Now ▸ https://ibmi.pse.is/7mn2dd 】

With Brazil’s medical diagnostics industry—a $2.1 billion market spanning over 7,000 hospitals and 23,000 laboratories—undergoing a transformative shift toward pharmacy-based rapid testing and telemedicine, innovation is in high demand. Carlos Gouvea, Executive President of the Brazilian In-Vitro Diagnostics Chamber (CBDL), seized this pivotal moment to visit Taiwan during the 2024 Healthcare+ Expo Taiwan, aiming to explore how Taiwanese innovations could address Brazil's evolving healthcare needs.

Carlos Gouvea, Executive President of the Brazilian In-Vitro Diagnostics Chamber (CBDL) visited 2024 Healthcare+ Expo Taiwan, aiming to explore how Taiwanese innovations could shape the future of healthcare.

“The AI-driven advancements I’ve seen here, many already in practical use, are progressing faster than in most developed nations,” Gouvea remarked, praising Taiwan’s strides in cancer cell therapies and next-generation sequencing (NGS). He highlighted Taiwan’s unique ecosystem where academic institutions, hospitals, and industries collaborate seamlessly to accelerate clinical trials and research.

While Brazil invests heavily in medical technology, Gouvea noted that “Taiwan’s government-led push for innovation creates a synergistic model where national policy and industry advancement go hand-in-hand”-a dynamic positioning Taiwan as a critical player in global healthcare.

Carlos Gouvea noted that he had observed various advanced medical technologies and experienced the collaborative ecosystem at the 2024 Healthcare+ Expo Taiwan.


Beyond seeking Taiwanese technologies for Brazil’s market, Gouvea emphasized fostering true collaboration: strategic alliances, shared expertise, and cross-border knowledge exchange. “Partnerships must be bidirectional,” he stressed, pointing to Brazil’s mature corporate governance and market strategies as potential assets for Taiwanese firms.

However, he cautioned that entering Brazil’s market requires overcoming language barriers, regulatory hurdles, and distribution challenges. “Innovation alone isn’t enough— success demands scalability, cost efficiency, and deep market knowledge,” he advised, urging Taiwanese companies to target niche sectors with high growth potential and lower competition.